SCHEMBL165878

SCHEMBL165878

CCOC(=O)c1nnc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.76
CA1 P00915 1/20 0.68
CA2 P00918 1/20 0.68
TARBP2 Q15633 1/20 0.61
HSD17B10 Q99714 3/20 0.61
MAPT P10636 5/20 0.59
RAB9A P51151 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
NPC1 O15118 1/20 0.59
TSHR P16473 1/20 0.59
SMPD1 P17405 1/20 0.56
ALDH1A1 P00352 2/20 0.52
LMNA P02545 2/20 0.50
MAPK1 P28482 1/20 0.50
MEN1 O00255 1/20 0.50
USP2 O75604 1/20 0.50
KMT2A Q03164 1/20 0.50
TRPM8 Q7Z2W7 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.48
PTGS2 P35354 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30949366 0.99 POLB (0.74) POLBCA1CA2TARBP2HSD17B10
SCHEMBL326764 0.88 CA1 (0.71) POLBCA1CA2TARBP2HSD17B10
SCHEMBL31049616 0.86 CA1 (0.68) POLBCA1CA2TARBP2HSD17B10
SCHEMBL28501879 0.86 CA1 (0.68) POLBCA1CA2TARBP2HSD17B10
SCHEMBL7865590 0.86 CA1 (0.72) POLBCA1CA2TARBP2HSD17B10
SCHEMBL163935 0.86 CA1 (0.68) POLBCA1CA2TARBP2HSD17B10
SCHEMBL167291 0.86 CA1 (0.68) POLBCA1CA2TARBP2HSD17B10
SCHEMBL114885 0.85 CA1 (0.67) POLBCA1CA2TARBP2HSD17B10
SCHEMBL166289 0.85 POLB (0.67) POLBCA1CA2HSD17B10MAPT
SCHEMBL11485622 0.84 CA1 (0.67) POLBCA1CA2TARBP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023231948-A1 ISR INHIBITORS, METHOD FOR PREPARING SAME, AND USE THEREOF 中国药科大学 2023-12-07 WO disclosed
CN-116768877-A ISR inhibitor and preparation method and application thereof 中国药科大学 2023-09-19 CN disclosed
US-9828351-B2 Enzyme interacting agents MONASH UNIVERSITY (AU) 2017-11-28 US disclosed
US-20170190698-A1 ENZYME INTERACTING AGENTS CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED (AU) 2017-07-06 US disclosed
EP-3160949-A1 ENZYME INTERACTING AGENTS Monash University (AU) 2017-05-03 EP disclosed
WO-2015196258-A1 ENZYME INTERACTING AGENTS MONASH UNIVERSITY (AU) 2015-12-30 WO disclosed
EP-2424870-B1 Therapeutic agents 713 ASTRAZENECA AB (SE) 2015-12-16 EP disclosed
EP-2590969-B1 Therapeutic agents 976 ASTRAZENECA AB (SE) 2014-10-15 EP disclosed
US-8546375-B2 (3-(4-(aminomethyl)phenoxy or phenylthio)azetidin-1-yl)(5-phenyl-1,3,4-oxadiazol-2-yl)methanone compounds ASTRAZENECA AB (SE) 2013-10-01 US disclosed
EP-2590969-A2 THERAPEUTIC AGENTS 976 AstraZeneca AB (SE) 2013-05-15 EP disclosed
EP-2424870-A1 THERAPEUTIC AGENTS 713 AstraZeneca AB (SE) 2012-03-07 EP disclosed
WO-2012004588-A2 THERAPEUTIC AGENTS 976 ASTRAZENECA AB (SE) 2012-01-12 WO disclosed
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS ASTRAZENECA AB (SE) 2012-01-12 US disclosed
WO-2010125390-A1 THERAPEUTIC AGENTS 713 ASTRAZENECA AB (SE) 2010-11-04 WO disclosed
US-5888941-A Carbozamides with antifungal activity J. URIACH & CIA. S.A. (ES) 1999-03-30 US disclosed
EP-0783502-A1 NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY J. URIACH & CIA. S.A. (ES) 1997-07-16 EP disclosed
WO-1997005131-A1 NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY J. URIACH & CIA. S.A. (ES) 1997-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170190698-A1 ENZYME INTERACTING AGENTS SMPD1, SMPD2, ASAH1 POLB 851/4885CA1 2255/4885CA2 1573/4885
US-20120010189-A1 (3-(4-(AMINOMETHYL)PHENOXY OR PHENYLTHIO)AZETIDIN-1-YL)(5-PHENYL-1,3,4-OXADIAZOL-2-YL)METHANONE COMPOUNDS TYR, MC2R, MC1R POLB 2885/4885CA1 4828/4885CA2 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.